33% radius evaluation to assess bone mineral density in prostate cancer patients

World Journal of Urology

Volumn 29, Issue 6, 2011, Pages 815-819

  Morote, Juan ^a   Planas, Jacques ^a   Mir, Maria Carmen ^a   Raventós, Carles X ^a   Encabo, Gloria ^a   Doll, Andreas ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bone mineral density; Osteoporosis; Prostate cancer; Radius

Indexed keywords

ANDROGEN; ANTIANDROGEN;

AGED; ARTICLE; BONE DENSITY; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; FEMUR NECK; HIP; HUMAN; INCIDENCE; LUMBAR VERTEBRA; MALE; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; PROSTATE TUMOR; RADIUS; RETROSPECTIVE STUDY;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; BONE DENSITY; FEMUR NECK; HIP JOINT; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RADIUS; RETROSPECTIVE STUDIES;

EID: 81855185327     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0630-7     Document Type: Article

References (22)

1. Morote J, Martinez E, Trilla E et al (2003) Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 44: 661-665.
2. Shahinian V, Kuo Y, Freeman JL, Goodwin J (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2): 154-164.
3. Morote J, Orsola A, Abascal J et al (2006) Bone mineral density changes in prostate cancer patients during the first two years of androgen suppression. J Urol 175: 1679-1683.
4. Morote J, Planas J, Orsola A et al (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69: 500-504.
5. Diamond T, Higano C, Smith M, Guise T, Singer F (2004) Osteoporosis in men with prostate carcinoma receiving androgen deprivation therapy: recommendations for diagnosis and therapies. Cancer 100: 892-899.
6. WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis repot of WHO study group. World Health Organization, Geneva.
7. Kanis J, Seeman E, Johnell O, Rizzoli R, Delmas P (2005) The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. Osteoporos Int 16: 456-459.
8. Melton L, Atkinson E, O′Connor M, O′Fallon W, Riggs B (1998) Bone density and fracture risk in men. J Bone Miner Res 13: 1915-1922.
9. Abrahamsson P (2004) Pathophysiology of bone metastases in prostate cancer. Eur Urol Suppl 3: 3-9.
10. Mittan D, Lee S, Miller E, Perez M, Basler J (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87: 3656-3661.
11. Greenspan S, Nelson J, Resnick M, Trump D, Parker R (2007) Once weekly oral alendronate prevents loss in men on androgen deprivation therapy for prostate cancer. Ann Intern Med 146: 416-424.
12. Smith M, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinners N (2003) Randomized controlled trial of zoledronic acid to prevent bone loss of in men receiving androgen deprivation therapy for non metastatic prostate cancer. J Urol 169: 2008-2012.
13. Bruder J, Jennie M, Basler J, Welch M (2006) Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67: 152-155.
14. Wadhwa V, Parr N (2009) Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy? Urology 73: 1347-1351.
15. Faulkner K, Orwoll E (2002) Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 5: 87-93.
16. Maillefert J, Sibilia J, Michel F, Saussine C, Javier R, Tavernier C (1999) Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonist for prostatic carcinoma. J Urol 161: 1219-1222.
17. Daniell H, Dunn S, Ferguson D, Lomas G, Niazi Z, Stratte P (2000) J Urol. Progressive osteoporosis during androgen deprivation therapy for prostate cancer 163: 181-186.
18. Smith MR, Francis D, McGovern J et al (2001) Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 345: 948-955.
19. Berruti A, Dogliotti L, Terrone C et al (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167: 2361-2367.
20. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312: 1254-1259.
21. Kelly P, Pocock N, Sambrook P, Eisman J (1990) Dietary calcium, sex hormones, and bone mineral density in men. BMJ 26: 1361-1364.
22. Greenspan S, Oppenheim D, Klibanski A (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110: 526-531.